Gujarat Themis Biosyn Past Earnings Performance
Past criteria checks 2/6
Gujarat Themis Biosyn has been growing earnings at an average annual rate of 28.9%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 22.3% per year. Gujarat Themis Biosyn's return on equity is 29.4%, and it has net margins of 34%.
Key information
28.9%
Earnings growth rate
28.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 22.3% |
| Return on equity | 29.4% |
| Net Margin | 34.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gujarat Themis Biosyn makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,742 | 592 | 115 | 0 |
| 31 Dec 23 | 1,563 | 550 | 97 | 0 |
| 30 Sep 23 | 1,456 | 518 | 90 | 0 |
| 30 Jun 23 | 1,486 | 553 | 85 | 0 |
| 31 Mar 23 | 1,490 | 580 | 79 | 0 |
| 31 Dec 22 | 1,496 | 561 | 74 | 0 |
| 30 Sep 22 | 1,400 | 534 | 73 | 0 |
| 30 Jun 22 | 1,274 | 485 | 81 | 0 |
| 31 Mar 22 | 1,149 | 436 | 72 | 0 |
| 31 Dec 21 | 1,094 | 396 | 76 | 0 |
| 30 Sep 21 | 1,152 | 400 | 75 | 0 |
| 30 Jun 21 | 1,073 | 375 | 78 | 0 |
| 31 Mar 21 | 906 | 302 | 74 | 0 |
| 31 Dec 20 | 936 | 353 | 72 | 0 |
| 30 Sep 20 | 998 | 376 | 72 | 0 |
| 30 Jun 20 | 891 | 278 | 76 | 0 |
| 31 Mar 20 | 851 | 237 | 66 | 0 |
| 31 Dec 19 | 691 | 152 | 62 | 0 |
| 30 Sep 19 | 483 | 67 | 56 | 0 |
| 30 Jun 19 | 424 | 65 | 55 | 0 |
| 31 Mar 19 | 410 | 64 | 53 | 0 |
| 31 Dec 18 | 406 | 49 | 52 | 0 |
| 30 Sep 18 | 407 | 47 | 53 | 0 |
| 30 Jun 18 | 397 | 43 | 53 | 0 |
| 31 Mar 18 | 388 | 39 | 45 | 0 |
| 31 Dec 17 | 393 | 39 | 47 | 0 |
| 30 Sep 17 | 379 | 40 | 46 | 0 |
| 30 Jun 17 | 367 | 39 | 46 | 0 |
| 31 Mar 17 | 357 | 44 | 45 | 0 |
| 31 Dec 16 | 335 | 44 | 43 | 0 |
| 30 Sep 16 | 329 | 43 | 44 | 0 |
| 30 Jun 16 | 327 | 45 | 48 | 0 |
| 31 Mar 16 | 326 | 46 | 44 | 0 |
| 31 Dec 15 | 324 | 41 | 57 | 0 |
| 30 Sep 15 | 325 | 46 | 55 | 0 |
| 30 Jun 15 | 321 | 46 | 54 | 0 |
| 31 Mar 15 | 314 | 46 | 42 | 0 |
| 31 Dec 14 | 307 | 51 | 51 | 0 |
| 30 Sep 14 | 301 | 48 | 51 | 0 |
| 30 Jun 14 | 302 | 49 | 43 | 0 |
| 31 Mar 14 | 302 | 45 | 51 | 0 |
| 31 Dec 13 | 303 | 31 | 59 | 0 |
| 30 Sep 13 | 299 | 29 | 49 | 0 |
| 30 Jun 13 | 297 | 21 | 50 | 0 |
Quality Earnings: 506879 has a high level of non-cash earnings.
Growing Profit Margin: 506879's current net profit margins (34%) are lower than last year (38.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506879's earnings have grown significantly by 28.9% per year over the past 5 years.
Accelerating Growth: 506879's earnings growth over the past year (2.1%) is below its 5-year average (28.9% per year).
Earnings vs Industry: 506879 earnings growth over the past year (2.1%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 506879's Return on Equity (29.4%) is considered high.